Human Microbiome Market (5th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Type of Biologic, Route of Administration, Drug Formulation, Target Indication, Target Therapeutic Area and Geographical Regions

Human Microbiome Market: Overview

As per Roots Analysis, the human microbiome market is estimated to grow from USD 0.85 billion in the current year to USD 3.27 billion by 2035, at a CAGR of 16% during the forecast period, till 2035.

Human Microbiome Market: Growth and Trends

The human microbiome consists of a variety of microorganisms, such as bacteria, archaea, viruses, and fungi, that inhabit different regions of the human body, including the skin, gut, mouth, and other tissues. The investigation into the diversity of the human microbiome dates back to the 1680s, when Antonie van Leeuwenhoek examined his oral and fecal microbiota samples. The existing human microbiome landscape is extremely dynamic, with studies emphasizing its crucial function in immunity, metabolism, and conditions like cancer, inflammatory diseases, and even neurodegenerative disorders. The US FDA has authorized two fecal microbiota treatments to prevent recurring C. difficile infection (rCDI). Significantly, REBYOTA (created by Ferring Pharmaceutical) became the first human microbiome therapy to gain approval in November 2022, with VOWST (developed by Seres Therapeutics) also receiving approval for oral administration in April 2023. Notably, the commercial triumph of VOWST has been strengthened by Nestlé Health Science’s purchase of its US and worldwide rights in June 2024.

Given the continuous advancements in DNA sequencing, bioinformatics, and analytical tools that enhance our comprehension of the human microbiome in relation to health and diseases, we anticipate that this sector is poised for double-digit market growth in the near future.

Growth Drivers: Strategic Enablers of Market Expansion

Advancements in microbiome sequencing technologies, such as next-generation sequencing and metagenomics, enable deeper analysis of microbial communities, accelerating diagnostics and therapies. Further, rising investments from pharma, biotech firms, and venture capital supports expanding clinical pipelines for conditions like gastrointestinal disorders, metabolic diseases, and cancer. In addition, increasing awareness of microbiomein health, coupled with demand for personalized probiotics, preventive healthcare, and collaborations between startups and academia, further propels human microbiome market expansion.

Market Challenges: Critical Barriers Impeding Progress

While the global human microbiome market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. High R&D and commercialization costs in the human microbiome market space including GMP facilities for live organisms and complex clinical trials, hinder scalability and adoption Stringent regulatory requirements, lack of standardized guidelines, and variability in microbial strains delay approvals and increase entry barriers across regions. Limited public understanding, ethical concerns over microbiome manipulation, and slow patient / provider adoption due to inconsistent evidence also impede progress.

Human Microbiome Market: Key Insights

The report delves into the current state of the human microbiome market and identifies potential growth opportunities within industry. Some key findings from the report include:

• Currently, close to 215 human microbiome therapeutics developed by ~55 developers are approved / being investigated across various stages of development for treating a myriad of disorders.
• Over 50% of the human microbiome therapeutics are in clinical stages of development; notably, most of the drugs / therapy programs are focused on the development of biologics, primarily live biotherapeutics.
• Close to 140 human microbiome diagnostic tests are being developed by 75 players in this domain; notably, around 55% of the developers were established post-2015.
• Around 80% of the companies are offering human microbiome diagnostics for analysis of microfloral composition and function; 55% of players are employing sequencing / metagenomics techniques for the diagnosis.
• Majority of fecal microbiota therapy developers were established between 2000-2015; of these, more than 65% are headquartered in North America, followed by Europe (~35%).
• Fecal bacteriotherapy involves the transplantation / infusion of fecal bacteria from healthy individuals to the stomach, colon / small intestine of patients; majority (50%) of these therapies are in clinical stages.
• Close to 205 clinical trials have been registered till date to evaluate the safety and efficacy of various fecal microbiota therapies; majority of these studies have been conducted across various trial sites in Europe.
• Over the last few years, start-ups have undertaken multiple initiatives to enhance their microbiome therapeutics and diagnostics portfolio; majority of the initiatives were undertaken for the treatment of ulcerative colitis.
• The rising interest in this market is reflected from the diverse partnerships established among various stakeholders in the recent past; in fact, more than 45% of the deals were inked in the last two years.
• Since 2022, more than USD 1.2 billion has been raised in this domain; notably, grants / awards are also a very prominent funding model adopted by microbiome drug developers.
• The market impact analysis outlines the potential factors that influence the evolution of the overall market; it can be employed to determine the growth drivers, restraints, opportunities and challenges within a specific domain.
• Driven by the increasing consumer awareness gut health, the rising prevalence of chronic diseases and advancements in microbiome sequencing technologies, the market is poised for a steady growth in the future.
• Currently, amongst various routes of administration, oral route captures the highest share (55%) of the market owing to its safety, convenience and the suitability for direct therapeutic intervention within the oral cavity.
• The infectious diseases sub-segment is estimated to capture of the overall market share in the current year, owing to the effectiveness of human microbiome therapeutics in the treatment of such diseases.
• Notably, amongst various geographical regions, North America is expected to dominate the overall human microbiome market during the forecast period.
• North America is expected to capture a significant share of the overall human microbiome market in the current year owing to the rapid innovations within human microbiome sequencing technologies in the region.
• Driven by the rapid success of approved microbiome therapeutic drugs developed by prominent players in the US, the human microbiome therapeutics market is expected to grow at a steady CAGR.

Human Microbiome Market

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Product

• Therapeutics
• Diagnostics
• Fecal Microbiota Therapies

By Type of Biologic

• Live Biotherapeutics
• Others

By Route of Administration

• Oral Route
• Rectal Route

By Drug Formulation

• Capsule
• Suspension
• Enema
• Powder

By Target Indication

• Clostridium Difficile Infection
• Necrotizing Enterocolitis
• Irritable Bowel Syndrome
• Acute Graft Versus Host Disease
• Diabetes Mellitus
• Irritable Bowel Disease
• Colorectal Cancer

By Target Therapeutic Area

• Infectious Disorders
• Gastrointestinal Disorders
• Rare Disorders
• Metabolic Disorders
• Oncological Disorders

By Geographical Regions

• North America
• US
• Canada
• Europe
• Germany
• France
• Italy
• UK
• Spain
• Rest of the Europe
• Asia-Pacific
• Australia
• China
• India
• Japan
• Latin America
• Brazil
• Middle East and North Africa
• Israel
• Saudi Arabia

Human Microbiome Market: Key Segments

Market Share by Type of Product: Diagnostics Segment Hold the Largest Share

In the current year, the diagnostics segment occupies the highest market share (~45%), as per human microbiome market report, driven by increased adoption of microbiome-centered diagnostic tests for the early identification of various conditions, such as metabolic disorders and cancer-related problems. The therapeutics segment is projected to see a significant growth rate of 32% during the forecast period. This increased research and development in personalized therapies, the effectiveness of existing treatments like Fecal Microbiota Transplantation (FMT) for particular illnesses, and new drugs and therapies under development.

Human Microbiome-based Therapeutics Market Share Insights

Market Share by Type of Biologic: Live Biotherapeutics Segment Holds the Largest Market Share

Currently, the live biotherapeutics segment occupies the entire human microbiome market share (for therapeutics) owing to the increasing application of microbiome-targeted treatments for treating various conditions, such as digestive problems, metabolic disorders, and cancer-related issues. Notably, the others segment (which includes phage biologics, vaccines, and additional antibodies) is expected to experience a remarkable growth rate, with a CAGR of 64% during the forecast period.

Market Share by Route of Administration: Oral Route Segment Holds the Largest Revenue

In the current year, the oral route occupies the highest market share (55%) of human microbiome therapeutics market. It is worth noting that the therapies administered via oral route are likely to witness a substantial CAGR of 38% during the forecast period. This is associated to the safety, user-friendliness, and the ability for direct therapeutic interaction in the oral cavity to accomplish desired systemic effects.

Market Share by Drug Formulation: Suspension Segment to Grow at a Higher CAGR

Among the various segments, the capsule segment occupies the highest human microbiome therapeutics market share (55%) in 2025. This results from the strong clinical trial pipeline of microbiome-centered therapies in capsule form. It is important to highlight that the suspension segment market is expected to expand at a notably higher CAGR (38%) throughout the forecast period. This arises from its ability to maintain the viability and stability of living microbial formulations, facilitate straightforward dosage adjustments, and its long-standing application history in diverse therapeutic uses.

Market Share by Target Indication: Clostridium Difficile Infection Segment Domina

Currently, the clostridium difficile infection segment occupies the entire human microbiome therapeutics market size. This is due to the rising frequency and intensity of clostridium difficile infections, coupled with the established link between antibiotic-induced gut dysbiosis and the infection.

Further, the market for therapies targeting acute graft versus host disease is likely to grow at a relatively higher CAGR (35%), during the period 2027-2035. This is attributed to the expected endorsement of MaaT013 (Xervyteg®), a pioneering microbiota-centered therapy designed to meet a significant unmet need in patients suffering from GI-involved acute graft versus host disease, where existing survival rates are dangerously low and no alternative approved therapy exists.

Market Share by Target Therapeutic Area: Infectious Disorders Segment Dominates the Market

Currently, the infectious diseases segment occupies the entire human microbiome therapeutics market size (with a share of 100%) and this trend is unlikely to change in the future. This is attributed to its direct involvement in immune function and pathogen defense, along with the demonstrated effectiveness of microbiome-based treatments, such as those addressing recurrent Clostridium difficile infections. Notably, the rare disorders segment is expected to experience a comparatively higher CAGR (35%) from 2027 to 2035.

Market Share by Geographical Regions: North America with Highest Revenue

According to our projections, North America is likely to capture the majority (95%) of the human microbiome therapeutics market share in 2025, as the advanced healthcare infrastructure in North America enables developers to conduct a large number of clinical trials, in order to meet the regulatory guidelines of the approval bodies. It is worth highlighting that the market in Europe is likely to grow at a relatively higher CAGR (75%), during the period 2025-2032.

Primary Research Overview

The opinions and insights presented in the market report were also influenced by discussions held with senior stakeholders in the industry. The market report includes detailed transcripts of interviews conducted with the following individuals:

• Former Senior Manager, Corporate Development, Mid-Sized Company, UK
• Co-founder and Chairman, Small Company, US
• Chief Executive Officer, Small Company, US
• Senior Scientist, Large Company, US
• President, Small Company, Taiwan
• Vice President, Business Development, Small Company, US
• Chief Business Officer, Mid-sized Company, Israel
• Former Vice President, Sales and Business Development, Small Company, US
• Co-founder and Chief Executive Officer, Small Company, Belgium
• Co-founder and Chief Executive Officer, Small Company, US
• Co-founder and Chief Executive Officer, Small Company, US
• Ex-Co-founder and Vice President of Innovation, Mid-sized Company, US
• Vice President & Chief Operating Officer, Small Company, US
• Former Vice President, Operations, Mid-sized Company, US
• Former President and Chief Executive Officer, Small Company, US
• Former Chief Scientific Officer and Vice President, Research, Small Company, US
• Former Chief Strategy Officer, Small Company, France

Example Players in Human Microbiome Market

• Becton, Dickinson and Company
• Biome Diagnostics
• Ferring Pharmaceuticals
• GoodGut
• Infant Bacterial Therapeutics
• MaaT Pharma
• Microbiomik
• NutriPATH
• Seres Therapeutics
• Tiny Health
• OxThera
• Vedanta Bisociences
• Zybio

Human Microbiome Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the human microbiome market, focusing on key market segments, including [A] type of product, [B] type of biologic, [C] route of administration, [D] drug formulation, [E] target indication, [F] target therapeutic area, and [G] geographical regions.
• Human Microbiome Therapeutics - Market Landscape: A detailed overview of the current market landscape of human microbiome therapeutics, along with information on several relevant parameters, such as [A] stage of development, [B] type of molecule, [C] type of biologic, [D] target indication, [E] therapeutic area, [F] route of administration, [G] type of formulation, [H] dosage frequency, [I] type of therapy, [J] year of establishment, [K] company size, [L] location of headquarters, and [M] most active players.
• Human Microbiome Diagnostics And Screening / Profiling Tests - Market Landscape 2: A detailed overview of the current market landscape of various types of diagnostic and screening / profiling tests, along with information on several relevant parameters, such as [A] stage of development, [B] type of sample analyzed, [C] type of screening technique, [D] target indication, [E] therapeutic area, [F] purpose of test, [G] year of establishment, [H] company size, and [I] location of headquarters.
• Human Microbiome Fecal Microbiota Therapies - Market Landscape 3: A detailed overview of the current market landscape of other relevant aspects of FMT therapies, along with information on several relevant parameters, such as [A] stage of development, [B] type of sample analyzed, [C] type of screening technique, [D] target indication, [E] therapeutic area, [F] purpose of test, [G] year of establishment, [H] company size, and [I] location of headquarters.
• Company and Drug Profiles: In-depth profiles of key players engaged in the development of microbiome therapeutics, microbiome diagnostics and screening / profiling tests and fecal microbiota therapy based on [A] year of establishment, [B] location of headquarters, [C] microbiome-based drug portfolio, [D] recent developments and [E] an informed future outlook.
• Clinical Trial Analysis: An in-depth analysis of completed and ongoing clinical studies of fecal microbiota therapy, based on various relevant parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] patient gender, [D] trial phase, [E] trial status, [F] therapeutic area, [G] type of sponsor / collaborator, [H] study design, [I] most active players (in terms of number of clinical trials), and [J] geography.
• Attractiveness Competitiveness Analysis: An insightful business portfolio analysis of top indications, across various therapeutic areas under investigation, based on the 9-box AC matrix framework. It further includes a discussion on the relative market attractiveness and existing competition across the most popular disease indications.
• Partnerships and Collaborations: An in-depth analysis of the partnerships and collaborations that have been inked by human microbiome developers, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] target indication, [D] therapeutic area, [E] type of partner and [F] most active players (in terms of number of partnerships).
• Funding and Investments: A detailed analysis of the funding and investments made in this domain, based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] amount invested, [D] purpose of funding, [E] target indication, [F] therapeutic area, [G] geography, [H] most active players and [I] leading investors.
• Case Study 1: An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, type of product manufactured and type of formulation. In addition, the chapter highlights key consideration for selecting a CMO / CRO partner.
• Case Study 2: assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade.

Key Questions Answered in this Report

• Which are the leading companies in human microbiome market?
• Which region dominates the human microbiome market?
• What are the key trends observed in the human microbiome market?
• What factors are likely to influence the evolution of this market?
• What are the primary challenges faced by human microbiome providers?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
• The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
• The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
• The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
• The report allows for more effective communication with the audience and in building strong business relations.

Show more